EGFR and central nervous system cancer: Conversely, EGFR, which is the most enriched mutated gene in the high ICP score group (30%) and whose alteration occurs in less than 6% of the low ICP score group as identified by somatic mutation analysis, has been reported to be frequently activated in GBM and predict worse survival outcomes in glioma patients (39).